NHS England is responsible for commissioning Highly Specialised Congenital Hyperinsulinism (CHI) Specialist Centres in London, Manchester, and Liverpool to provide a range of treatments for this condition. Care includes long-term monitoring of the glycaemic status of children with CHI to avoid hypoglycaemic incident and subsequent neurological harm. Additionally, the Specialist Centres engage with parents in the long-term care of children who also receive regular follow up at the centres with the involvement of a patient\u2019s local healthcare provider to support care closer to home management.\u202fAll patients with CHI are referred to and have access to these centres.<\/p>
The Department has not had specific discussions with NHS England on Congenital Hyperinsulinism. Whilst no assessment has been made for prioritising early diagnosis thereof, it is acknowledged by the National Health Service and by practitioners involved in routine paediatric health assessment, surveillance and subsequent treatment, that the early diagnosis of CHI is important and that children usually start to show symptoms of CHI within the first few days of life, although very occasionally symptoms may appear later in infancy. The Specialist Centres also provide advice, education and support to local health care providers on CHI and the management of patients with CHI.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2023-02-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL5618"} , {"_value" : "HL5620"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-02-22T15:23:47.543Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-02-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Congenital Hyperinsulinism: Children"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what assessment they have made of the case for prioritising early diagnosis of Congenital Hyperinsulinism to prevent Hypoglycaemic incident and subsequent neurological harm in babies and children.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2484", "label" : {"_value" : "Biography information for Lord Rennard"} } , "tablingMemberPrinted" : [{"_value" : "Lord Rennard"} ], "uin" : "HL5619"} , {"_about" : "http://data.parliament.uk/resources/1416153", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1416153/answer", "answerText" : {"_value" : "The Government intends to move to a new system that taxes all products in reference to their alcohol content for the first time. This will help to target problem drinking by taxing higher-strength products associated with alcohol-related harm a higher rate of duty.
The Government is continuing to engage with interested stakeholders, including public health professionals, on these reforms. A consultation was launched in October and stakeholders are encouraged to respond before the deadline of 30 January 2022. A tax information and impact note will be published following the consultation when the policy is final, or near final, in the usual way.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4169", "label" : {"_value" : "Biography information for Viscount Younger of Leckie"}
}
, "answeringMemberPrinted" : {"_value" : "Viscount Younger of Leckie"}
, "dateOfAnswer" : {"_value" : "2022-01-31", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2022-01-31T17:20:47.983Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "14"}
, "answeringDeptShortName" : {"_value" : "Treasury"}
, "answeringDeptSortName" : {"_value" : "Treasury"}
, "date" : {"_value" : "2022-01-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Alcoholic Drinks: Excise Duties"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty's Government how the proposed alcohol duty system will impact on their ability to cover the costs of alcohol to (1) the NHS, and (2) on society.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4159", "label" : {"_value" : "Biography information for Baroness Hayter of Kentish Town"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Hayter of Kentish Town"}
], "uin" : "HL5619"}
, {"_about" : "http://data.parliament.uk/resources/1203110", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1203110/answer", "answerText" : {"_value" : "
The information requested is provided in the following tables by the NHS Business Services Authority:<\/p>
<\/p><\/td> | Number of items<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||
Month and Year<\/p><\/td> | Antidepressants<\/p><\/td> | Anxiolytics<\/p><\/td> | Barbiturates and Hypnotics<\/p><\/td> | Antipsychotics<\/p><\/td><\/tr> | |||||||||||||||||||||||||||||||||||||
October 2018<\/p><\/td> | 6,242,966<\/p><\/td> | 559,541<\/p><\/td> | 738,497<\/p><\/td> | 1,059,542<\/p><\/td><\/tr> | |||||||||||||||||||||||||||||||||||||
November 2018<\/p><\/td> | 6,105,746<\/p><\/td> | 538,508<\/p><\/td> | 715,005<\/p><\/td> | 1,030,777<\/p><\/td><\/tr> | |||||||||||||||||||||||||||||||||||||
December 2018<\/p><\/td> | 6,043,242<\/p><\/td> | 527,892<\/p><\/td> | 704,835<\/p><\/td> | 1,022,515<\/p><\/td><\/tr> | |||||||||||||||||||||||||||||||||||||
January 2019<\/p><\/td> | 6,279,989<\/p><\/td> | 547,545<\/p><\/td> | 743,385<\/p><\/td> | 1,052,933<\/p><\/td><\/tr> | |||||||||||||||||||||||||||||||||||||
February 2019<\/p><\/td> | 5,680,329<\/p><\/td> | 492,331<\/p><\/td> | 656,344<\/p><\/td> | 955,569<\/p><\/td><\/tr> | |||||||||||||||||||||||||||||||||||||
March 2019<\/p><\/td> | 6,153,299<\/p><\/td> | 527,789<\/p><\/td> | 699,736<\/p><\/td> | 1,021,958<\/p><\/td><\/tr><\/tbody><\/table> <\/strong><\/p> <\/p><\/td> Number of items<\/p><\/td><\/tr> Month and Year<\/p><\/td> Antidepressants<\/p><\/td> Anxiolytics<\/p><\/td> Barbiturates and Hypnotics<\/p><\/td> Antipsychotics<\/p><\/td><\/tr> October 2019<\/p><\/td> 6,574,909<\/p><\/td> 547,721<\/p><\/td> 720,362<\/p><\/td> 1,091,403<\/p><\/td><\/tr> November 2019<\/p><\/td> 6,324,255<\/p><\/td> 515,711<\/p><\/td> 683,198<\/p><\/td> 1,045,301<\/p><\/td><\/tr> December 2019<\/p><\/td> 6,428,992<\/p><\/td> 525,749<\/p><\/td> 698,338<\/p><\/td> 1,067,155<\/p><\/td><\/tr> January 2020<\/p><\/td> 6,701,671<\/p><\/td> 539,735<\/p><\/td> 733,003<\/p><\/td> 1,098,917<\/p><\/td><\/tr> February 2020<\/p><\/td> 6,097,134<\/p><\/td> 490,517<\/p><\/td> 653,315<\/p><\/td> 997,909<\/p><\/td><\/tr> March 2020<\/p><\/td> 6,828,732<\/p><\/td> 529,601<\/p><\/td> 704,071<\/p><\/td> 1,080,136<\/p><\/td><\/tr><\/tbody><\/table> <\/strong><\/p> The data provided is for prescriptions prescribed and dispensed in England only. The time periods covered are October 2019 \u2013 March 2020 inclusive and also October 2018 \u2013 March 2019 for comparison. March 2020 is the most recent dataset available.<\/p> The term \u2018items\u2019 refers to the number of times a product appears on a prescription form, and not the quantity prescribed. Any secondary indications or unlicensed uses of any of these medicines will not be apparent from the data.<\/p> The NHS Business Services Authority does not have enough information to determine if a prescription is \u2018new\u2019 for a particular patient.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Bethell"}
, "dateOfAnswer" : {"_value" : "2020-06-22", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2020-06-22T10:58:43.487Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2020-06-11", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mental Illness: Prescription Drugs"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "Her Majesty's Government how many prescriptions have been issued for (1) antidepressants, (2) anxiolytics, (3) sedatives and hypnotics, and (4) antipsychotics, in the last six months; how many prescriptions in each of these categories were new prescriptions; and how these figures compare with the same period last year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/2109", "label" : {"_value" : "Biography information for The Earl of Sandwich"}
}
, "tablingMemberPrinted" : [{"_value" : "The Earl of Sandwich"}
], "uin" : "HL5619"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|